Gadopentetate Dimeglumine Injectable Solution Suppliers & Bulk Manufacturers
Available Forms: Injectable Solution
Available Strengths: 0.5 mol/L
Reference Brands: Magnevist(US & EU)
Category:
Contrast Agent
Gadopentetate dimeglumine is a gadolinium-based contrast agent that enhances MRI images by increasing tissue and vascular radiopacity. It provides detailed visualization of blood vessels, organs, and abnormalities, supporting accurate diagnosis. Benefits include high image quality, rapid excretion, safety, and improved detection of neurological, cardiovascular, and musculoskeletal conditions worldwide.
Gadopentetate Dimeglumine Injectable Solution is available in Injectable Solution
and strengths such as 0.5 mol/L.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Gadopentetate Dimeglumine Injectable Solution is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Gadopentetate Dimeglumine Injectable Solution can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Gadopentetate dimeglumine, marketed as Magnevist, is approved in the US by the FDA and in the EU via EMA for MRI imaging of blood vessels, organs, and tissues. Regulatory approval requires comprehensive dossiers, including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews clinical trial and quality data for timely approval, while the EMA ensures regional compliance with safety and manufacturing standards. For dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence supports swift approval, safe administration, and global availability, enabling high-quality diagnostic imaging in neurology, cardiology, and musculoskeletal assessments worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing